Intravascular Cooling System
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
Global Choroidal Neovascularization Drug Market Research Report 2023
1 Choroidal Neovascularization Drug Market Overview
1.1 Product Overview and Scope of Choroidal Neovascularization Drug
1.2 Choroidal Neovascularization Drug Segment by Type
1.2.1 Global Choroidal Neovascularization Drug Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 AVMOC-001
1.2.3 BB-3
1.2.4 BBT-007
1.2.5 DG-3
1.2.6 Entolimod
1.2.7 EWA-001
1.2.8 Others
1.3 Choroidal Neovascularization Drug Segment by Application
1.3.1 Global Choroidal Neovascularization Drug Sales Comparison by Application: (2022-2028)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Choroidal Neovascularization Drug Market Size Estimates and Forecasts
1.4.1 Global Choroidal Neovascularization Drug Revenue 2017-2028
1.4.2 Global Choroidal Neovascularization Drug Sales 2017-2028
1.4.3 Choroidal Neovascularization Drug Market Size by Region: 2017 Versus 2021 Versus 2028
2 Choroidal Neovascularization Drug Market Competition by Manufacturers
2.1 Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2017-2022)
2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Choroidal Neovascularization Drug Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Choroidal Neovascularization Drug Manufacturing Sites, Area Served, Product Type
2.5 Choroidal Neovascularization Drug Market Competitive Situation and Trends
2.5.1 Choroidal Neovascularization Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Choroidal Neovascularization Drug Players Market Share by Revenue
2.5.3 Global Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Choroidal Neovascularization Drug Retrospective Market Scenario by Region
3.1 Global Choroidal Neovascularization Drug Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Choroidal Neovascularization Drug Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Choroidal Neovascularization Drug Market Facts & Figures by Country
3.3.1 North America Choroidal Neovascularization Drug Sales by Country
3.3.2 North America Choroidal Neovascularization Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Choroidal Neovascularization Drug Market Facts & Figures by Country
3.4.1 Europe Choroidal Neovascularization Drug Sales by Country
3.4.2 Europe Choroidal Neovascularization Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Choroidal Neovascularization Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Choroidal Neovascularization Drug Sales by Region
3.5.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Choroidal Neovascularization Drug Market Facts & Figures by Country
3.6.1 Latin America Choroidal Neovascularization Drug Sales by Country
3.6.2 Latin America Choroidal Neovascularization Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Choroidal Neovascularization Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Country
3.7.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Choroidal Neovascularization Drug Historic Market Analysis by Type
4.1 Global Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)
4.2 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2017-2022)
4.3 Global Choroidal Neovascularization Drug Price by Type (2017-2022)
5 Global Choroidal Neovascularization Drug Historic Market Analysis by Application
5.1 Global Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)
5.2 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2017-2022)
5.3 Global Choroidal Neovascularization Drug Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Cellphire, Inc.
6.1.1 Cellphire, Inc. Corporation Information
6.1.2 Cellphire, Inc. Description and Business Overview
6.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio
6.1.5 Cellphire, Inc. Recent Developments/Updates
6.2 Chrysalis BioTherapeutics, Inc.
6.2.1 Chrysalis BioTherapeutics, Inc. Corporation Information
6.2.2 Chrysalis BioTherapeutics, Inc. Description and Business Overview
6.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
6.2.5 Chrysalis BioTherapeutics, Inc. Recent Developments/Updates
6.3 Cleveland BioLabs, Inc.
6.3.1 Cleveland BioLabs, Inc. Corporation Information
6.3.2 Cleveland BioLabs, Inc. Description and Business Overview
6.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio
6.3.5 Cleveland BioLabs, Inc. Recent Developments/Updates
6.4 Cumberland Pharmaceuticals, Inc.
6.4.1 Cumberland Pharmaceuticals, Inc. Corporation Information
6.4.2 Cumberland Pharmaceuticals, Inc. Description and Business Overview
6.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio
6.4.5 Cumberland Pharmaceuticals, Inc. Recent Developments/Updates
6.5 Diffusion Pharmaceuticals Inc.
6.5.1 Diffusion Pharmaceuticals Inc. Corporation Information
6.5.2 Diffusion Pharmaceuticals Inc. Description and Business Overview
6.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio
6.5.5 Diffusion Pharmaceuticals Inc. Recent Developments/Updates
6.6 Eli Lilly and Company
6.6.1 Eli Lilly and Company Corporation Information
6.6.2 Eli Lilly and Company Description and Business Overview
6.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio
6.6.5 Eli Lilly and Company Recent Developments/Updates
6.7 GNI Group Ltd.
6.6.1 GNI Group Ltd. Corporation Information
6.6.2 GNI Group Ltd. Description and Business Overview
6.6.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio
6.7.5 GNI Group Ltd. Recent Developments/Updates
6.8 Humanetics Corporation
6.8.1 Humanetics Corporation Corporation Information
6.8.2 Humanetics Corporation Description and Business Overview
6.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio
6.8.5 Humanetics Corporation Recent Developments/Updates
6.9 INSYS Therapeutics, Inc.
6.9.1 INSYS Therapeutics, Inc. Corporation Information
6.9.2 INSYS Therapeutics, Inc. Description and Business Overview
6.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
6.9.5 INSYS Therapeutics, Inc. Recent Developments/Updates
6.10 Meabco A/S
6.10.1 Meabco A/S Corporation Information
6.10.2 Meabco A/S Description and Business Overview
6.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Meabco A/S Choroidal Neovascularization Drug Product Portfolio
6.10.5 Meabco A/S Recent Developments/Updates
6.11 Neumedicines Inc.
6.11.1 Neumedicines Inc. Corporation Information
6.11.2 Neumedicines Inc. Choroidal Neovascularization Drug Description and Business Overview
6.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio
6.11.5 Neumedicines Inc. Recent Developments/Updates
6.12 Onconova Therapeutics, Inc.
6.12.1 Onconova Therapeutics, Inc. Corporation Information
6.12.2 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Description and Business Overview
6.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
6.12.5 Onconova Therapeutics, Inc. Recent Developments/Updates
6.13 PharmaIN Corporation
6.13.1 PharmaIN Corporation Corporation Information
6.13.2 PharmaIN Corporation Choroidal Neovascularization Drug Description and Business Overview
6.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.13.4 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio
6.13.5 PharmaIN Corporation Recent Developments/Updates
6.14 Pluristem Therapeutics Inc.
6.14.1 Pluristem Therapeutics Inc. Corporation Information
6.14.2 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Description and Business Overview
6.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio
6.14.5 Pluristem Therapeutics Inc. Recent Developments/Updates
6.15 ProCertus BioPharm Inc.
6.15.1 ProCertus BioPharm Inc. Corporation Information
6.15.2 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Description and Business Overview
6.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.15.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio
6.15.5 ProCertus BioPharm Inc. Recent Developments/Updates
6.16 RDD Pharma Ltd.
6.16.1 RDD Pharma Ltd. Corporation Information
6.16.2 RDD Pharma Ltd. Choroidal Neovascularization Drug Description and Business Overview
6.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.16.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio
6.16.5 RDD Pharma Ltd. Recent Developments/Updates
6.17 RedHill Biopharma Ltd.
6.17.1 RedHill Biopharma Ltd. Corporation Information
6.17.2 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Description and Business Overview
6.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.17.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio
6.17.5 RedHill Biopharma Ltd. Recent Developments/Updates
6.18 RxBio, Inc.
6.18.1 RxBio, Inc. Corporation Information
6.18.2 RxBio, Inc. Choroidal Neovascularization Drug Description and Business Overview
6.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.18.4 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio
6.18.5 RxBio, Inc. Recent Developments/Updates
6.19 Soligenix, Inc.
6.19.1 Soligenix, Inc. Corporation Information
6.19.2 Soligenix, Inc. Choroidal Neovascularization Drug Description and Business Overview
6.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio
6.19.5 Soligenix, Inc. Recent Developments/Updates
7 Choroidal Neovascularization Drug Manufacturing Cost Analysis
7.1 Choroidal Neovascularization Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug
7.4 Choroidal Neovascularization Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Choroidal Neovascularization Drug Distributors List
8.3 Choroidal Neovascularization Drug Customers
9 Choroidal Neovascularization Drug Market Dynamics
9.1 Choroidal Neovascularization Drug Industry Trends
9.2 Choroidal Neovascularization Drug Market Drivers
9.3 Choroidal Neovascularization Drug Market Challenges
9.4 Choroidal Neovascularization Drug Market Restraints
10 Global Market Forecast
10.1 Choroidal Neovascularization Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Choroidal Neovascularization Drug by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Choroidal Neovascularization Drug by Type (2023-2028)
10.2 Choroidal Neovascularization Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Choroidal Neovascularization Drug by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Choroidal Neovascularization Drug by Application (2023-2028)
10.3 Choroidal Neovascularization Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Choroidal Neovascularization Drug by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Choroidal Neovascularization Drug by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Choroidal Neovascularization Drug Sales Growth Rate Comparison by Type (2022-2028) & (K Pcs) & (US$ Million)
Table 2. Global Choroidal Neovascularization Drug Sales Growth Rate Comparison by Application (2022-2028) & (K Pcs) & (US$ Million)
Table 3. Global Choroidal Neovascularization Drug Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Choroidal Neovascularization Drug Market Competitive Situation by Manufacturers in 2021
Table 5. Global Choroidal Neovascularization Drug Sales (K Pcs) of Key Manufacturers (2017-2022)
Table 6. Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Choroidal Neovascularization Drug Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Choroidal Neovascularization Drug Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Choroidal Neovascularization Drug Average Price (USD/Pcs) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Choroidal Neovascularization Drug Manufacturing Sites and Area Served
Table 11. Manufacturers Choroidal Neovascularization Drug Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Choroidal Neovascularization Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Choroidal Neovascularization Drug as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Choroidal Neovascularization Drug Sales by Region (2017-2022) & (K Pcs)
Table 16. Global Choroidal Neovascularization Drug Sales Market Share by Region (2017-2022)
Table 17. Global Choroidal Neovascularization Drug Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2017-2022)
Table 19. North America Choroidal Neovascularization Drug Sales by Country (2017-2022) & (K Pcs)
Table 20. North America Choroidal Neovascularization Drug Sales Market Share by Country (2017-2022)
Table 21. North America Choroidal Neovascularization Drug Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Choroidal Neovascularization Drug Revenue Market Share by Country (2017-2022)
Table 23. Europe Choroidal Neovascularization Drug Sales by Country (2017-2022) & (K Pcs)
Table 24. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2017-2022)
Table 25. Europe Choroidal Neovascularization Drug Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Choroidal Neovascularization Drug Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Choroidal Neovascularization Drug Sales by Region (2017-2022) & (K Pcs)
Table 28. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Choroidal Neovascularization Drug Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Choroidal Neovascularization Drug Revenue Market Share by Region (2017-2022)
Table 31. Latin America Choroidal Neovascularization Drug Sales by Country (2017-2022) & (K Pcs)
Table 32. Latin America Choroidal Neovascularization Drug Sales Market Share by Country (2017-2022)
Table 33. Latin America Choroidal Neovascularization Drug Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Choroidal Neovascularization Drug Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2017-2022) & (K Pcs)
Table 36. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Choroidal Neovascularization Drug Revenue Market Share by Country (2017-2022)
Table 39. Global Choroidal Neovascularization Drug Sales by Type (2017-2022) & (K Pcs)
Table 40. Global Choroidal Neovascularization Drug Sales Market Share by Type (2017-2022)
Table 41. Global Choroidal Neovascularization Drug Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Choroidal Neovascularization Drug Revenue Share by Type (2017-2022)
Table 43. Global Choroidal Neovascularization Drug Price by Type (2017-2022) & (USD/Pcs)
Table 44. Global Choroidal Neovascularization Drug Sales (K Pcs) by Application (2017-2022)
Table 45. Global Choroidal Neovascularization Drug Sales Market Share by Application (2017-2022)
Table 46. Global Choroidal Neovascularization Drug Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Choroidal Neovascularization Drug Revenue Share by Application (2017-2022)
Table 48. Global Choroidal Neovascularization Drug Price by Application (2017-2022) & (USD/Pcs)
Table 49. Cellphire, Inc. Corporation Information
Table 50. Cellphire, Inc. Description and Business Overview
Table 51. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 52. Cellphire, Inc. Choroidal Neovascularization Drug Product
Table 53. Cellphire, Inc. Recent Developments/Updates
Table 54. Chrysalis BioTherapeutics, Inc. Corporation Information
Table 55. Chrysalis BioTherapeutics, Inc. Description and Business Overview
Table 56. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 57. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product
Table 58. Chrysalis BioTherapeutics, Inc. Recent Developments/Updates
Table 59. Cleveland BioLabs, Inc. Corporation Information
Table 60. Cleveland BioLabs, Inc. Description and Business Overview
Table 61. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 62. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product
Table 63. Cleveland BioLabs, Inc. Recent Developments/Updates
Table 64. Cumberland Pharmaceuticals, Inc. Corporation Information
Table 65. Cumberland Pharmaceuticals, Inc. Description and Business Overview
Table 66. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 67. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product
Table 68. Cumberland Pharmaceuticals, Inc. Recent Developments/Updates
Table 69. Diffusion Pharmaceuticals Inc. Corporation Information
Table 70. Diffusion Pharmaceuticals Inc. Description and Business Overview
Table 71. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 72. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product
Table 73. Diffusion Pharmaceuticals Inc. Recent Developments/Updates
Table 74. Eli Lilly and Company Corporation Information
Table 75. Eli Lilly and Company Description and Business Overview
Table 76. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 77. Eli Lilly and Company Choroidal Neovascularization Drug Product
Table 78. Eli Lilly and Company Recent Developments/Updates
Table 79. GNI Group Ltd. Corporation Information
Table 80. GNI Group Ltd. Description and Business Overview
Table 81. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 82. GNI Group Ltd. Choroidal Neovascularization Drug Product
Table 83. GNI Group Ltd. Recent Developments/Updates
Table 84. Humanetics Corporation Corporation Information
Table 85. Humanetics Corporation Description and Business Overview
Table 86. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 87. Humanetics Corporation Choroidal Neovascularization Drug Product
Table 88. Humanetics Corporation Recent Developments/Updates
Table 89. INSYS Therapeutics, Inc. Corporation Information
Table 90. INSYS Therapeutics, Inc. Description and Business Overview
Table 91. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 92. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product
Table 93. INSYS Therapeutics, Inc. Recent Developments/Updates
Table 94. Meabco A/S Corporation Information
Table 95. Meabco A/S Description and Business Overview
Table 96. Meabco A/S Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 97. Meabco A/S Choroidal Neovascularization Drug Product
Table 98. Meabco A/S Recent Developments/Updates
Table 99. Neumedicines Inc. Corporation Information
Table 100. Neumedicines Inc. Description and Business Overview
Table 101. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 102. Neumedicines Inc. Choroidal Neovascularization Drug Product
Table 103. Neumedicines Inc. Recent Developments/Updates
Table 104. Onconova Therapeutics, Inc. Corporation Information
Table 105. Onconova Therapeutics, Inc. Description and Business Overview
Table 106. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 107. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product
Table 108. Onconova Therapeutics, Inc. Recent Developments/Updates
Table 109. PharmaIN Corporation Corporation Information
Table 110. PharmaIN Corporation Description and Business Overview
Table 111. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 112. PharmaIN Corporation Choroidal Neovascularization Drug Product
Table 113. PharmaIN Corporation Recent Developments/Updates
Table 114. Pluristem Therapeutics Inc. Corporation Information
Table 115. Pluristem Therapeutics Inc. Description and Business Overview
Table 116. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 117. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product
Table 118. Pluristem Therapeutics Inc. Recent Developments/Updates
Table 119. ProCertus BioPharm Inc. Corporation Information
Table 120. ProCertus BioPharm Inc. Description and Business Overview
Table 121. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 122. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product
Table 123. ProCertus BioPharm Inc. Recent Developments/Updates
Table 124. RDD Pharma Ltd. Corporation Information
Table 125. RDD Pharma Ltd. Description and Business Overview
Table 126. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 127. RDD Pharma Ltd. Choroidal Neovascularization Drug Product
Table 128. RDD Pharma Ltd. Recent Developments/Updates
Table 129. RedHill Biopharma Ltd. Corporation Information
Table 130. RedHill Biopharma Ltd. Description and Business Overview
Table 131. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 132. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product
Table 133. RedHill Biopharma Ltd. Recent Developments/Updates
Table 134. RxBio, Inc. Corporation Information
Table 135. RxBio, Inc. Description and Business Overview
Table 136. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 137. RxBio, Inc. Choroidal Neovascularization Drug Product
Table 138. RxBio, Inc. Recent Developments/Updates
Table 139. Soligenix, Inc. Corporation Information
Table 140. Soligenix, Inc. Description and Business Overview
Table 141. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 142. Soligenix, Inc. Choroidal Neovascularization Drug Product
Table 143. Soligenix, Inc. Recent Developments/Updates
Table 144. Production Base and Market Concentration Rate of Raw Material
Table 145. Key Suppliers of Raw Materials
Table 146. Choroidal Neovascularization Drug Distributors List
Table 147. Choroidal Neovascularization Drug Customers List
Table 148. Choroidal Neovascularization Drug Market Trends
Table 149. Choroidal Neovascularization Drug Market Drivers
Table 150. Choroidal Neovascularization Drug Market Challenges
Table 151. Choroidal Neovascularization Drug Market Restraints
Table 152. Global Choroidal Neovascularization Drug Sales Forecast by Type (2023-2028) & (K Pcs)
Table 153. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Type (2023-2028)
Table 154. Global Choroidal Neovascularization Drug Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 155. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Type (2023-2028)
Table 156. Global Choroidal Neovascularization Drug Sales Forecast by Application (2023-2028) & (K Pcs)
Table 157. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Application (2023-2028)
Table 158. Global Choroidal Neovascularization Drug Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 159. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Application (2023-2028)
Table 160. Global Choroidal Neovascularization Drug Sales Forecast by Region (2023-2028) & (K Pcs)
Table 161. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Region (2023-2028)
Table 162. Global Choroidal Neovascularization Drug Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 163. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Region (2023-2028)
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Choroidal Neovascularization Drug
Figure 2. Global Choroidal Neovascularization Drug Market Share by Type in 2021 & 2028
Figure 3. AVMOC-001 Product Picture
Figure 4. BB-3 Product Picture
Figure 5. BBT-007 Product Picture
Figure 6. DG-3 Product Picture
Figure 7. Entolimod Product Picture
Figure 8. EWA-001 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Choroidal Neovascularization Drug Market Share by Application in 2021 & 2028
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Global Choroidal Neovascularization Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Choroidal Neovascularization Drug Market Size (2017-2028) & (US$ Million)
Figure 16. Global Choroidal Neovascularization Drug Sales (2017-2028) & (K Pcs)
Figure 17. Choroidal Neovascularization Drug Sales Share by Manufacturers in 2021
Figure 18. Global Choroidal Neovascularization Drug Revenue Share by Manufacturers in 2021
Figure 19. The Global 5 and 10 Largest Choroidal Neovascularization Drug Players: Market Share by Revenue in 2021
Figure 20. Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 21. Global Choroidal Neovascularization Drug Sales Market Share by Region (2017-2022)
Figure 22. Global Choroidal Neovascularization Drug Sales Market Share by Region in 2021
Figure 23. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2017-2022)
Figure 24. Global Choroidal Neovascularization Drug Revenue Market Share by Region in 2021
Figure 25. U.S. Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Canada Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Germany Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. France Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. U.K. Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Italy Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Russia Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. China Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Japan Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. South Korea Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. India Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Australia Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Taiwan Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Indonesia Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Thailand Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Malaysia Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Philippines Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Vietnam Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Mexico Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Brazil Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Argentina Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Turkey Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Saudi Arabia Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 48. UAE Choroidal Neovascularization Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 49. Sales Market Share of Choroidal Neovascularization Drug by Type (2017-2022)
Figure 50. Manufacturing Cost Structure of Choroidal Neovascularization Drug
Figure 51. Manufacturing Process Analysis of Choroidal Neovascularization Drug
Figure 52. Choroidal Neovascularization Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Cellphire, Inc. Chrysalis BioTherapeutics, Inc. Cleveland BioLabs, Inc. Cumberland Pharmaceuticals, Inc. Diffusion Pharmaceuticals Inc. Eli Lilly and Company GNI Group Ltd. Humanetics Corporation INSYS Therapeutics, Inc. Meabco A/S Neumedicines Inc. Onconova Therapeutics, Inc. PharmaIN Corporation Pluristem Therapeutics Inc. ProCertus BioPharm Inc. RDD Pharma Ltd. RedHill Biopharma Ltd. RxBio, Inc. Soligenix, Inc.